Use of Pharmacogenetics to Select Erbitux or Cisplatin to Treat Head and Neck Cancer

NCT01790516 · clinicaltrials.gov ↗

NA

Phase

TERMINATED

Status

2

Enrollment

OTHER

Sponsor class

Stopped low accruals--2 patients were enrolled in over a year

Conditions

Head and Neck Squamous Cell Cancer

Interventions

DRUG: Cisplatin
DRUG: cetuximab
RADIATION: Radiation

Sponsor

Georgetown University